Literature DB >> 19158833

Recurrent genomic aberrations combined with deletions of various tumour suppressor genes may deregulate the G1/S transition in CD4+CD56+ haematodermic neoplasms and contribute to the aggressiveness of the disease.

F Jardin1, M Callanan, D Penther, P Ruminy, X Troussard, J P Kerckaert, M Figeac, F Parmentier, V Rainville, I Vaida, P Bertrand, A B Duval, J M Picquenot, L Chaperot, J P Marolleau, J Plumas, H Tilly, C Bastard.   

Abstract

CD4+CD56+ haematodermic neoplasms (HDN) constitute a rare disease characterized by aggressive clinical behaviour and a poor prognosis. Tumour cells from HDN are leukaemic counterparts of plasmacytoid dendritic cells (pDCs). Despite increased knowledge of the ontogenetic origin of these tumours, the genetic causes and oncogenic signalling events involved in malignant transformation are still unknown. To delineate novel candidate regions and disease-related genes, we studied nine typical CD4+CD56+ HDN cases using genome-wide high-resolution array comparative genomic hybridization (CGH). Genomic imbalances, which were predominantly losses, were frequently detected. Gross genomic losses or gains involving an entire chromosome were observed in eight cases. The most frequent imbalances were deletions of chromosome 9, chromosome 13 and partial losses affecting 17p or 12p. Combinations of deletions of tumour suppressor genes (TSG), namely RB1, CDKN1B (p27), CDKN2A, (p16(ink4a), p14(arf)) or TP53 (p53), were observed in all cases. These results indicate that deletion events altering G1/S regulation are crucial for HDN oncogenesis. Furthermore, in addition to frequent sporadic gene losses, in one case we observed a 8q24 interstitial deletion that brought MYC closer to miR-30b/miR-30d, which may be related to their deregulation. Taken together, these results indicate that in addition to frequent G1/S checkpoint alterations, various genetic events could contribute to the chemoresistance of the tumour.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19158833     DOI: 10.1038/leu.2008.359

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  18 in total

1.  A Druggable TCF4- and BRD4-Dependent Transcriptional Network Sustains Malignancy in Blastic Plasmacytoid Dendritic Cell Neoplasm.

Authors:  Michele Ceribelli; Zhiying Esther Hou; Priscilla N Kelly; Da Wei Huang; George Wright; Karthik Ganapathi; Moses O Evbuomwan; Stefania Pittaluga; Arthur L Shaffer; Guido Marcucci; Stephen J Forman; Wenming Xiao; Rajarshi Guha; Xiaohu Zhang; Marc Ferrer; Laurence Chaperot; Joel Plumas; Elaine S Jaffe; Craig J Thomas; Boris Reizis; Louis M Staudt
Journal:  Cancer Cell       Date:  2016-11-14       Impact factor: 31.743

2.  Molecular profiling of blastic plasmacytoid dendritic cell neoplasm reveals a unique pattern and suggests selective sensitivity to NF-kB pathway inhibition.

Authors:  M R Sapienza; F Fuligni; C Agostinelli; C Tripodo; S Righi; M A Laginestra; A Pileri; M Mancini; M Rossi; F Ricci; A Gazzola; F Melle; C Mannu; F Ulbar; M Arpinati; M Paulli; T Maeda; D Gibellini; L Pagano; N Pimpinelli; M Santucci; L Cerroni; C M Croce; F Facchetti; P P Piccaluga; S A Pileri
Journal:  Leukemia       Date:  2014-02-07       Impact factor: 11.528

3.  Transcriptomic and genomic heterogeneity in blastic plasmacytoid dendritic cell neoplasms: from ontogeny to oncogenesis.

Authors:  Florian Renosi; Anne Roggy; Ambre Giguelay; Lou Soret; Pierre-Julien Viailly; Meyling Cheok; Sabeha Biichle; Fanny Angelot-Delettre; Vahid Asnafi; Elizabeth Macintyre; Sandrine Geffroy; Mary Callanan; Tony Petrella; Eric Deconinck; Etienne Daguindau; Véronique Harrivel; Sabrina Bouyer; Véronique Salaun; Pascale Saussoy; Jean Feuillard; Pascal Fuseau; Philippe Saas; Olivier Adotévi; Fabrice Jardin; Christophe Ferrand; Claude Preudhomme; Jacques Colinge; Christophe Roumier; Francine Garnache-Ottou
Journal:  Blood Adv       Date:  2021-03-09

4.  Identification of differentially expressed microRNA in parathyroid tumors.

Authors:  Reza Rahbari; Alisha K Holloway; Mei He; Elham Khanafshar; Orlo H Clark; Electron Kebebew
Journal:  Ann Surg Oncol       Date:  2010-11-18       Impact factor: 5.344

Review 5.  Treatment of blastic plasmacytoid dendritic cell neoplasm.

Authors:  Jill M Sullivan; David A Rizzieri
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

6.  Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study.

Authors:  Livio Pagano; Caterina Giovanna Valentini; Alessandro Pulsoni; Simona Fisogni; Paola Carluccio; Francesco Mannelli; Monia Lunghi; Gianmatteo Pica; Francesco Onida; Chiara Cattaneo; Pier Paolo Piccaluga; Eros Di Bona; Elisabetta Todisco; Pellegrino Musto; Antonio Spadea; Alfonso D'Arco; Stefano Pileri; Giuseppe Leone; Sergio Amadori; Fabio Facchetti
Journal:  Haematologica       Date:  2012-10-12       Impact factor: 9.941

7.  Haploinsufficiency for NR3C1, the gene encoding the glucocorticoid receptor, in blastic plasmacytoid dendritic cell neoplasms.

Authors:  Anouk Emadali; Neda Hoghoughi; Samuel Duley; Azadeh Hajmirza; Els Verhoeyen; Francois-Loic Cosset; Philippe Bertrand; Christophe Roumier; Anne Roggy; Céline Suchaud-Martin; Martine Chauvet; Sarah Bertrand; Sieme Hamaidia; Sophie Rousseaux; Véronique Josserand; Julie Charles; Isabelle Templier; Takahiro Maeda; Juliana Bruder-Costa; Laurence Chaperot; Joel Plumas; Marie-Christine Jacob; Thierry Bonnefoix; Sophie Park; Remy Gressin; Cornelis P Tensen; Cristina Mecucci; Elizabeth Macintyre; Dominique Leroux; Elisabeth Brambilla; Florence Nguyen-Khac; Isabelle Luquet; Dominique Penther; Christian Bastard; Fabrice Jardin; Christine Lefebvre; Francine Garnache; Mary B Callanan
Journal:  Blood       Date:  2016-04-08       Impact factor: 22.113

8.  1q12 chromosome translocations form aberrant heterochromatic foci associated with changes in nuclear architecture and gene expression in B cell lymphoma.

Authors:  Alexandra Fournier; Anne McLeer-Florin; Christine Lefebvre; Samuel Duley; Leila Barki; Juliana Ribeyron; Kassambara Alboukadel; Sieme Hamaidia; Aurélie Granjon; Rémy Gressin; Alicia Lajmanovich; Thierry Bonnefoix; Stéphanie Chauvelier; Alexandra Debernardi; Sophie Rousseaux; Florence de Fraipont; Martin Figeac; Jean-Pierre Kerckaert; John De Vos; Yves Usson; Katia Delaval; Alexei Grichine; Claire Vourc'h; Saadi Khochbin; Robert Feil; Dominique Leroux; Mary B Callanan
Journal:  EMBO Mol Med       Date:  2010-05       Impact factor: 12.137

Review 9.  Blastic Plasmacytoid Dendritic Cell Neoplasm: Progress in Cell Origin, Molecular Biology, Diagnostic Criteria and Therapeutic Approaches.

Authors:  Wei Cheng; Tian-Tian Yu; Ai-Ping Tang; Ken He Young; Li Yu
Journal:  Curr Med Sci       Date:  2021-07-03

10.  MutS Homologues hMSH4 and hMSH5: Genetic Variations, Functions, and Implications in Human Diseases.

Authors:  Nicole Clark; Xiling Wu; Chengtao Her
Journal:  Curr Genomics       Date:  2013-04       Impact factor: 2.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.